ICBs block receptors that inhibit T‐cell activation (such as CTLA‐4 and PD‐1).[29, 30, 31] The inhibition of CTLA‐4 or PD‐1 signaling in T cells has demonstrated remarkable efficacy in patients with various tumors, including melanoma and lung cancer. This evidence concerns the gene PDCD1 and melanoma.